Overview
2015Founded1
Compare with Travere Therapeutics, Inc., Mirum Pharmaceuticals or Nature's Sunshine Products, or pick any stock.
- TickerBBIO on Nasdaq1
- Industrypharmaceutical industry1
- HeadquartersPalo Alto1
- Websitebridgebio.com
- Incorporated inDE4
- Business address3160 Porter Dr., Suite 250, Palo Alto, Ca 943044
- Filer categoryLarge accelerated filer4
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 72% of the revenue BridgeBio broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product | $0 | $2.9M | $362.4M |
| License and Service | $9.3M | $218.8M | $128.3M |
| Royalty | $0 | $169.0K | $11.4M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue2¢$21.0M
- Research and development45¢$452.0M
- Selling, general and admin53¢$531.2M
- Income tax0¢$435.0K
Out of $502.1M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues, net | $502.1M | $221.9M | $9.3M |
| Total cost of revenues | $21.0M | $3.9M | $2.4M |
| Research and development | $452.0M | $506.5M | $455.7M |
| Selling, general and administrative | $531.2M | $288.9M | $150.6M |
| Restructuring, impairment, and related charges | $21.3M | $15.6M | $7.9M |
| Total operating costs and expenses | $1.0B | $814.9M | $616.7M |
| Loss from operations | -$523.4M | -$593.0M | -$607.4M |
| Interest income | $19.9M | $17.2M | $18.0M |
| Interest expense | -$53.1M | -$91.0M | -$81.3M |
| Gain on deconsolidation of subsidiaries | $0 | $178.3M | $0 |
| Loss on extinguishments of debt | -$21.2M | -$26.6M | $0 |
| Net loss from equity method investments | -$72.6M | -$31.2M | $0 |
| Other income, net | $43.1M | $12.3M | $17.4M |
| Total other income (expense), net | -$209.1M | $50.8M | -$45.9M |
| Loss before income taxes | -$732.5M | -$542.2M | -$653.3M |
| Provision for income taxes | $435.0K | $1.2M | $0 |
| Net loss | -$732.9M | -$543.3M | -$653.3M |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | $8.0M | $7.6M | $10.0M |
| Net loss attributable to common stockholders of BridgeBio | -$724.9M | -$535.8M | -$643.2M |
| Net loss per share attributable to common stockholders of BridgeBio, basic (in dollars per share) | -$3.78 | -$2.88 | -$3.95 |
| Net loss per share attributable to common stockholders of BridgeBio, diluted (in dollars per share) | -$3.78 | -$2.88 | -$3.95 |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic (in shares) | 191.5M shares | 186.1M shares | 162.8M shares |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted (in shares) | 191.5M shares | 186.1M shares | 162.8M shares |
| Noncash interest expense on deferred royalty obligations | $125.1M | $8.3M | $0 |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $570.1M | $681.1M | $375.9M |
| Marketable securities | $17.4M | $0 | |
| Accounts receivable, net | $139.4M | $4.7M | |
| Inventories | $26.8M | $0 | |
| Prepaid expenses and other current assets | $44.1M | $34.9M | |
| Total current assets | $797.7M | $720.7M | |
| Equity method investments | $80.0M | $143.7M | |
| Property and equipment, net | $5.4M | $7.0M | |
| Operating lease right-of-use assets | $8.1M | $5.8M | |
| Intangible assets, net | $28.1M | $23.9M | |
| Other assets | $16.7M | $18.2M | |
| Total assets | $936.0M | $919.3M | |
| Accounts payable | $36.2M | $9.6M | |
| Accrued compensation and benefits | $76.7M | $58.3M | |
| Accrued research and development liabilities | $41.4M | $34.3M | |
| Operating lease liabilities, current portion | $6.2M | $4.5M | |
| Deferred revenue, current portion | $7.2M | $14.6M | |
| Other current liabilities | $120.2M | $33.1M | |
| Total current liabilities | $288.0M | $154.4M | |
| Operating lease liabilities, net of current portion | $3.8M | $4.7M | |
| Deferred revenue, net of current portion | $13.1M | $17.1M | |
| Other long-term liabilities | $244.0K | $286.0K | |
| Total liabilities | $3.0B | $2.4B | |
| Redeemable convertible noncontrolling interests | -$570.0K | $142.0K | |
| Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | $0 | $0 | |
| Common stock, $0.001 par value; 500,000,000 shares authorized; 198,759,831 shares issued and 192,633,286 shares outstanding as of December 31, 2025, 196,236,234 shares issued and 190,044,473 shares outstanding as of December 31, 2024 | $202.0K | $196.0K | |
| Treasury stock, at cost; 7,597,172 shares as of December 31, 2025; 6,191,761 shares as of December 31, 2024 | -$323.3M | -$275.0M | |
| Additional paid-in capital | $2.1B | $1.9B | |
| Accumulated other comprehensive income | $12.0K | $8.0K | |
| Accumulated deficit | -$3.8B | -$3.1B | |
| Total BridgeBio stockholders deficit | -$2.1B | -$1.5B | |
| Noncontrolling interests | $10.6M | $10.2M | |
| Total stockholders deficit | -$2.1B | -$1.5B | -$1.3B |
| Total liabilities, redeemable convertible noncontrolling interests and stockholders deficit | $936.0M | $919.3M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, authorized (in shares) | 25.0M shares | 25.0M shares | |
| Preferred stock, issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, authorized (in shares) | 500.0M shares | 500.0M shares | |
| Common stock, issued (in shares) | 202.4M shares | 196.2M shares | |
| Common stock, outstanding (in shares) | 194.8M shares | 190.0M shares | |
| Treasury stock (in shares) | 7.6M shares | 6.2M shares | |
| Deferred royalty obligations, net | $855.0M | $479.1M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$732.9M | -$543.3M | -$653.3M |
| Stock-based compensation | $133.0M | $95.8M | $108.7M |
| Loss on extinguishments of debt | $21.2M | $26.6M | $0 |
| Noncash interest expense on deferred royalty obligations | $125.1M | $8.3M | $0 |
| Amortization of debt discount and issuance costs | $6.0M | $7.5M | $8.9M |
| Depreciation and amortization | $5.4M | $6.1M | $6.5M |
| Noncash lease expense | $4.9M | $4.1M | $4.0M |
| Net loss from equity method investments | $72.6M | $31.2M | $0 |
| Change in fair value of the embedded derivative associated with the deferred royalty obligation | -$19.7M | -$1.6M | $0 |
| Noncash income from equity method investments | -$8.8M | $0 | $0 |
| (Gain) loss on deconsolidation of subsidiaries | $0 | -$178.3M | $1.2M |
| Gain from investment in equity securities, net | $0 | -$8.1M | -$18.3M |
| Accrual of payment-in-kind interest on term loan | $0 | $0 | $10.2M |
| Other noncash adjustments, net | -$1.7M | -$935.0K | -$803.0K |
| Accounts receivable, net | -$134.7M | -$3.0M | $15.3M |
| Inventories | -$25.3M | $0 | $0 |
| Prepaid expenses and other current assets | -$8.8M | -$13.9M | -$2.7M |
| Other assets | $1.1M | $1.5M | -$1.5M |
| Accounts payable | $26.6M | $1.5M | $2.8M |
| Accrued compensation and benefits | $23.0M | $17.0M | $7.8M |
| Accrued research and development liabilities | $7.2M | $8.7M | -$9.9M |
| Operating lease liabilities | -$6.5M | -$5.9M | -$4.8M |
| Deferred revenue | -$11.4M | $21.9M | -$5.4M |
| Other liabilities | $77.8M | $4.2M | $3.5M |
| Net cash used in operating activities | -$445.9M | -$520.7M | -$527.7M |
| Purchases of marketable securities | -$28.2M | -$93.8M | -$29.7M |
| Maturities of marketable securities | $11.0M | $95.0M | $82.5M |
| Purchases of investments in equity securities | $0 | -$20.3M | -$107.5M |
| Proceeds from sales of investments in equity securities | $0 | $63.2M | $110.6M |
| Proceeds from special cash dividends received from an investment in equity securities | $2.3M | $25.7M | $0 |
| Payment for intangible assets | -$8.5M | -$8.0M | $0 |
| Purchases of property and equipment | -$1.1M | -$933.0K | -$1.3M |
| Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries | $0 | -$140.0K | -$503.0K |
| Net cash provided by (used in) investing activities | -$24.5M | $60.8M | $54.0M |
| Repurchase of common stock | -$48.3M | $0 | $0 |
| Repayment of term loans | -$459.0M | -$473.4M | $0 |
| Proceeds from issuance of common stock through public offerings, net | $0 | $314.7M | $449.8M |
| Proceeds from common stock issuances under ESPP | $6.4M | $4.5M | $3.4M |
| Proceeds from stock option exercises, net of repurchases | $27.7M | $3.7M | $6.0M |
| Transactions with noncontrolling interests | $2.1M | $0 | -$801.0K |
| Repurchase of RSU shares to satisfy tax withholding | -$14.2M | -$7.5M | -$6.9M |
| Net cash provided by financing activities | $359.3M | $748.5M | $451.5M |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | -$111.1M | $288.5M | -$22.2M |
| Cash paid for interest | $43.7M | $91.3M | $61.1M |
| Cash paid for income taxes | $1.2M | $0 | $0 |
| Unpaid property and equipment | $43.0K | $279.0K | $100.0K |
| Transfers to noncontrolling interests | -$5.6M | -$5.8M | -$10.5M |
| Repayments of deferred royalty obligations | $15.5M | $0 | $0 |
Former names
- BridgeBio Pharma LLCJun 19, 2018 to May 16, 20194
Timeline
- 2015Founded Founded1
Recent filings
- Oct 13, 20268-K
- Sep 21, 20264
- Aug 31, 20268-K
- Aug 20, 20264
- Aug 19, 2026144
- Aug 18, 2026144
- Aug 18, 20264
- Aug 18, 20264
- Aug 18, 20264
- Aug 17, 20268-K
- Aug 17, 2026144
- Aug 17, 2026SCHEDULE 13D/A
- Aug 14, 2026424B7
- Aug 10, 20268-K
- Aug 10, 202610-Q
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitebridgebio.com1
- X (Twitter)x.com/BridgeBioPharma1
- LinkedInwww.linkedin.com/company/bridgebio1
- WikidataQ106238343
- SEC EDGARCIK 1743881
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataBridgeBio on Wikidata
- 2SEC EDGARBridgeBio filings on SEC EDGAR
- 3Company websiteBridgeBio logo
- 4SEC EDGARBridgeBio filings on SEC EDGAR
- 5SEC EDGARBridgeBio 10-K for fiscal 2025
- 6SEC EDGARBridgeBio 10-K for fiscal 2019
- 7SEC EDGARBridgeBio 10-K for fiscal 2020
- 8SEC EDGARBridgeBio 10-K for fiscal 2021
- 9SEC EDGARBridgeBio 10-K for fiscal 2022
- 10SEC EDGARBridgeBio 10-Q for fiscal 2026
- 11SEC EDGARBridgeBio 10-Q for fiscal 2026
- 12SEC EDGARBridgeBio 10-K for fiscal 2019
- 13SEC EDGARBridgeBio 10-K for fiscal 2019